Bioheart Announces First Intracoronary Implantation of Adipose Stem Cells in Azerbaijan

SUNRISE, FL / ACCESSWIRE / November 12, 2014 / Bioheart, Inc. BHRT, a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced today that the first successful intracoronary implantation of autologous adipose-derived stem cell (ADSC) was performed to a 70 year-old male patient with ischemic cardiomyopathy by Emrah Anar MD (Chief of Cardiology and Cardiovascular Surgery) in Baku (Azerbaijan) Cardiac Center of Central Military Hospital.

"Bioheart is bringing regenerative therapies to patients around the world," said Kristin Comella, Chief Science officer of Bioheart. "By working with some of the top physicians in the world, we are able to advance the science and improve patient outcomes."

Adipose tissue was removed with liposuction from the abdominal region. ADSCs were derived from patient's adipose tissue and resuspended in 40 cc of 0.9 % NaCl solution. ADSCs were implanted into the targeted treatment area (LAD, Cx artery and RCA) with the Infusion Catheter (total volume 30 mL). And 10 cc of ADSC suspension was delivered via IV push over a 10 minute period. The procedure was completed without complications.

About Bioheart, Inc. 

Bioheart, Inc. is dedicated to advancing the field of regenerative medicine by offering the highest quality technology, cellular treatments and training. Specific to biotechnology, Bioheart, Inc. specializes in the discovery, development and commercialization of autologous cellular therapies that treat a wide variety of degenerative diseases.

Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry by delivering stem cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions, chronic and acute heart damage, peripheral vascular disease and other issues. Bioheart's goals are to improve a patient's quality of life by regenerating their damaged tissue, when possible, and by reducing health care costs and hospitalizations. Bioheart's leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.

For more information on Bioheart, visit www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2013, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2014. 

Media Contact:

Carissa Matton
Bioheart, Inc.
13794 NW 4th Street, Suite 212
Sunrise, Florida 33325
Phone: 772.285.8511
cmatton@bioheartinc.com

SOURCE: Bioheart, Inc.